Abstract
For broadly human leukocyte antigensensitized patients (HS; calculated panel-reactive antibody >80%), options for deceased donor (DD) transplantation are extremely limited. Data from United Network for Organ Sharing (20002009) indicate that <10% of HS patients are transplanted each year. Immune modulation of HS patients using intravenous immunoglobulin (IVIG) and rituximab has shown promise in reducing donor-specific antibody (DSA) titers and improving the chances for successful transplantation for patients awaiting DD transplants. Critical to the success of desensitization with IVIG + rituximab is a coherent antibody-testing strategy aimed at detection of DSA reductions and identification of crossmatch parameters that are associated with a low likelihood of antibody-mediated rejection posttransplant. Here, we discuss data that examine the efficacy of IVIG + rituximab in reducing DSA levels and improving chances for a successful DD transplantation. Patient and graft survival data are also presented as is an analysis of the safety of IVIG + rituximab in sensitized patients.
Original language | English (US) |
---|---|
Pages (from-to) | 60-61 |
Number of pages | 2 |
Journal | Transplantation proceedings |
Volume | 44 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2012 |
Externally published | Yes |
ASJC Scopus subject areas
- Surgery
- Transplantation